jte 522 has been researched along with Experimental Hepatoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, R; Fujise, Y; Murawaki, Y; Nagahara, T; Okano, J | 1 |
| Chang-De, J; Damdinsuren, B; Dono, K; Kobayashi, S; Kondo, M; Matsuura, N; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Sekimoto, M; Sugita, Y; Umeshita, K; Wakasa, K; Yamamoto, H | 1 |
2 other study(ies) available for jte 522 and Experimental Hepatoma
| Article | Year |
|---|---|
Preventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on DEN-induced hepatocarcinogenesis in rats.
Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Chemoprevention; Cyclooxygenase 2 Inhibitors; Diethylnitrosamine; Gene Expression Regulation, Neoplastic; Glutathione Transferase; In Situ Nick-End Labeling; Liver Neoplasms, Experimental; Male; Oxazoles; Oxidative Stress; Proliferating Cell Nuclear Antigen; Rats; Rats, Wistar; Time Factors | 2010 |
JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1.
Topics: Actins; Animals; Benzenesulfonates; Body Weight; Choline Deficiency; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; DNA Damage; Genes, myc; Isoenzymes; Liver; Liver Cirrhosis, Experimental; Liver Neoplasms, Experimental; Male; Oxazoles; Precancerous Conditions; Proliferating Cell Nuclear Antigen; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Wistar | 2003 |